<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c) and (d) AND AMENDMENTS THERETO
FILED PURSUANT TO 13d-2
(Amendment No. _1_______________)1
NEUROBIOLOGICAL TECHNOLOGIES, INC.
-----------------------------------------------------------
(Name of Issuer)
COMMON STOCK , PAR VALUE $0.001 PER SHARE
-----------------------------------------------------------
(Title of Class of Securities)
00064124W1
-----------------------------------------------------------
(CUSIP Number)
NOVEMBER 12, 1999
-----------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/x/ Rule 13d-1(c)
/ / Rule 13d-1(d)
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
- --------------------
<PAGE>
<TABLE>
<S> <C>
- ---------------------------------------- --------------------------------------
CUSIP No. 00064124W1 13G Page 2 of 5 Pages
- ---------------------------------------- --------------------------------------
- ---------------------------------------------------------------------------------------------------------------------
1.
NAME OF REPORTING
PERSON
IRS IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
MERZ + CO. GmbH & CO.
NONE
- ---------------------------------------------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
- ---------------------------------------------------------------------------------------------------------------------
3. SEC USE ONLY
- ---------------------------------------------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
GERMANY
- ---------------------------------------------------------------------------------------------------------------------
Number of Shares
Beneficially Owned By Each
Reporting Person With 5. SOLE VOTING POWER NONE
----------------------------------------------------------------------------------------
6. SHARED VOTING POWER NONE
----------------------------------------------------------------------------------------
7. SOLE DISPOSITIVE POWER NONE
----------------------------------------------------------------------------------------
8. SHARED DISPOSITIVE POWER NONE
- ---------------------------------------------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
NONE
- ---------------------------------------------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
/ /
- ---------------------------------------------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0%
- ---------------------------------------------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
00
- ---------------------------------------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE>
Page 3 of 5
ITEM 1(a). NAME OF ISSUER
Neurobiological Technologies, Inc.
ITEM 1(b). ADDRESS OF ISSUERS' PRINCIPAL EXECUTIVE OFFICES
1387 Marina Way South
Richmond, California 94804
ITEM 2(a). NAME OF PERSONS FILING
Merz + Co. GmbH & Co.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE
Eckenheimer Landstrasse 100-104
60318 Frankfurt a.M.
Germany
ITEM 2(c). CITIZENSHIP
Germany
ITEM 2(d). TITLE OF CLASS OF SECURITIES
Common Stock
ITEM 2(e). CUSIP NUMBER
00064124W1
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b) OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable
ITEM 4. OWNERSHIP
(a) Amount Beneficially Owned: NONE
(b) Percent of Class: 0.0%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: NONE
(ii) shared power to vote or to direct the vote: NONE
(iii) sole power to dispose or to direct the disposition of: NONE
(iv) shared power to dispose or to direct the disposition of: NONE
<PAGE>
Page 4 of 5
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date thereof
the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following. /x/
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE
SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not Applicable
ITEM 10. CERTIFICATION
Inasmuch as the reporting person is no longer the beneficial owner of any of the
number of shares outstanding, the reporting person has no further reporting
obligation under Section 13(d) of the Securities and Exchange Commission and the
rules promulgated thereunder.
<PAGE>
Page 5 of 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Date: February 3, 2000
Merz + Co. GmbH & Co.
/s/ Dr. Peter Mauritz
-------------------------------
By: Dr. Peter Mauritz
Its: Vice President, Finance
/s/ H.W. Glaab
-------------------------------
By: H.W.Glaab
Its: Executive Director, Legal Department
